Can Sustained Product Demand Drive BDX Stock Before Q4 Earnings?

Becton, Dickinson and Company (BDX) is projected to report Q4 fiscal 2025 revenues of $5.91 billion and EPS of $3.91, building on a 7.6% EPS beat in the prior quarter. Strong performance in BD Medical, driven by biologics demand and new product adoption, and BD Interventional, fueled by product expansions, are expected to drive overall revenue growth, with segment increases of 15.5% and 7.1% year-over-year, respectively. Conversely, the BD Life Sciences segment is anticipated to decline by 4.9% due to ongoing market challenges in China and Europe, contributing to a Zacks Rank #4 (Sell) and recent share underperformance against its sector and the S&P 500, despite long-term strategic investments and a valuation discount to industry peers.

Analysis

BDX reported adjusted Q3 fiscal 2025 EPS of $3.68, surpassing the Zacks Consensus Estimate by 7.6%, marking its fourth consecutive beat with an average surprise of 6.5%. For Q4 fiscal 2025, the company projects revenues of $5.91 billion, an 8.7% year-over-year improvement, and EPS of $3.91, representing a 2.6% increase from the prior year. This growth is primarily driven by strong performance in the BD Medical segment, estimated to grow 15.5% year-over-year to $3.28 billion, fueled by biologics demand and new product adoption like the BD Libertas Wearable Injector.

The BD Interventional segment is also expected to contribute positively, with revenues projected to rise 7.1% year-over-year to $1.35 billion, supported by expanded indications for Phasix and new product launches in Urology & Critical Care. Conversely, the BD Life Sciences segment faces headwinds, with estimated revenues declining 4.9% year-over-year to $1.27 billion, largely due to challenging market dynamics in China and constrained research funding in Europe, despite new product launches such as the BD FACSDiscover A8 Cell Analyzer.

Despite a forward 12-month P/E of 12X, which is a discount to the industry average of 17.1X, BDX shares have underperformed significantly, losing 0.1% over three months compared to a 9% gain for its Medical - Dental Supplies peers. The Zacks model assigns a #4 (Sell) Rank and a 0.00% Earnings ESP, indicating a lower probability of beating Q4 estimates. This underperformance suggests market skepticism despite the valuation discount relative to some peers like McKesson and Cooper Companies.

Long-term visibility is supported by strategic investments, including a $35 million expansion in syringe manufacturing and the FDA application for the at-home BD Onclarity HPV Assay. The agreement to combine the BDB & DS business with Waters Corporation is also expected to enhance strategic focus. However, persistent market dynamics in China and an unstable macroeconomic environment continue to pose potential headwinds to future performance.

Key Decisions for Investors

• Closely monitor BDX's Q4 fiscal 2025 earnings, particularly the BD Life Sciences segment's performance given the Zacks #4 (Sell) Rank and 0.00% Earnings ESP.
• Evaluate if strategic initiatives and new product launches can effectively counteract persistent macroeconomic headwinds and underperformance relative to peers, despite the current valuation discount.
• Assess the long-term impact of the Waters Corporation agreement and the $35 million manufacturing investment on future growth and profitability, considering the company's recent share price underperformance against sector benchmarks.